Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 3;12:811364. doi: 10.3389/fimmu.2021.811364

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Zhang, Zhu, Zheng, Wang, Li, Feng, Shang, He, Jiang, Shi, Wang, Cao and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Anti-CD19 CAR-T cells efficiently inhibit Raji tumor progression in vivo. (A) Schema of study in vivo demonstrating the antitumor activity of CAR-T cells in a disseminated human B-cell malignancy xenogeneic NPG/Vst mice model (n=6). (B) Bioluminescent imaging of NPG mice in vivo weekly 2 times (n=6). (C) The levels of serum IFN-γ concentration in mice measured on the 7th day after the second CAR-T cells injection (n=6). (D) The numbers of T cells in blood of mice detected by flow cytometry analysis at day 52 when the study terminated (n=6). (C, D) Values were expressed as the means ± SD. Unpaired t test was performed. ***p<0.001, **p<0.01, *p<0.05 compared to RNAU6 anti-CD19 CAR-T cells.